Zhejiang Garden Biopharmaceutical (300401.SZ): Zhejiang Garden Pharmaceutical obtained the pharmaceutical registration certificate for Alendronate Sodium Tablets.

Gelonghui Finance · Nov 22 15:42

Gelonghui, November 22nd - Zhejiang Garden Biopharmaceutical (300401.SZ) announced that its wholly-owned subsidiary, Zhejiang Garden Pharmaceuticals Co., Ltd. (hereinafter referred to as "Garden Pharmaceuticals"), recently received the "Drug Registration Certificate" for "Alendronate Sodium Tablets" issued by the National Medical Products Administration.

Alendronate Sodium Tablets are mainly used to treat osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. Alendronate Sodium Tablets are a Category B variety in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2023)".

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

花园生物(300401.SZ)：花园药业取得阿仑膦酸钠片的药品注册证书

Zhejiang Garden Biopharmaceutical (300401.SZ): Zhejiang Garden Pharmaceutical obtained the pharmaceutical registration certificate for Alendronate Sodium Tablets.

Risk Disclaimer

Statement